Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

被引：12

作者：

Kyaw, Moe H. H. ^{[1
]}

Spinardi, Julia ^{[2
]}

Zhang, Ling ^{[3
]}

Oh, Helen May Lin ^{[4
]}

Srivastava, Amit ^{[5
]}

机构：

[1] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, Gaithersburg, MD USA

[2] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, Sao Paulo, Brazil

[3] Boehringer Ingelheim GmbH & Co KG, Real World Evidence Analyt Ctr Excellence, Ridgefield, CT USA

[4] Changi Gen Hosp, Dept Infect Dis, Singapore, Singapore

[5] Orbital Therapeut, Cambridge, MA 02139 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期

关键词：

BNT162b2; mRNA vaccine; COVID-19; heterologous booster; inactivated virus vaccine; effectiveness; CORONAVAC; DELTA;

D O I：

10.1080/21645515.2023.2165856

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.

引用

页数：16

共 50 条

[31] Tracking the dynamics of antibody production against the SARS-CoV-2 virus after two doses of the mRNA vaccine BNT162b2 [J].

Maly, M. ;

Fialova, A. ;

Zakoucka, H. ;

Nemecek, V ;

Orlikova, H. ;

Kyncl, J. ;

Limberkova, R. .

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE, 2025, 74 (01) :44-52

[32] Effectiveness of BNT162b2 vaccine to preventing COVID-19 in healthcare personnel [J].

Chico-Sanchez, Pablo ;

Gras-Valenti, Paula ;

Algado-Selles, Natividad ;

Merino-Lucas, Esperanza ;

Carlos Rodriguez-Diaz, Juan ;

Ronda-Perez, Elena ;

Sanchez-Paya, Jose .

GACETA SANITARIA, 2022, 36 (05) :484-487

[33] Self Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose [J].

Mofaz, Merav ;

Yechezkel, Matan ;

Guan, Grace ;

Brandeau, Margaret L. ;

Patalon, Tal ;

Gazit, Sivan ;

Yamin, Dan ;

Shmueli, Erez .

EMERGING INFECTIOUS DISEASES, 2022, 28 (07) :1375-1383

[34] Pigmented purpuric dermatosis after BNT162B2 mRNA COVID-19 vaccine administration [J].

Atak, Mehmet Fatih ;

Farabi, Banu ;

Kalelioglu, Mehmet Berati ;

Rao, Babar K. .

JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (02) :435-437

[35] Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients [J].

Haller, Maria C. ;

Kaiser, Robert A. ;

Langthaler, Simon ;

Brandstetter, Clara ;

Apfalter, Petra ;

Kerschner, Heidrun ;

Cejka, Daniel .

TRANSPLANT INTERNATIONAL, 2022, 35

[36] Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine [J].

Nantel, Sabryna ;

Bourdin, Benoite ;

Adams, Kelsey ;

Carbonneau, Julie ;

Rabezanahary, Henintsoa ;

Hamelin, Marie-Eve ;

McCormack, Deirdre ;

Savard, Patrice ;

Longtin, Yves ;

Cheng, Matthew P. ;

De Serres, Gaston ;

Corbeil, Jacques ;

Gilca, Vladimir ;

Baz, Mariana ;

Boivin, Guy ;

Quach, Caroline ;

Decaluwe, Helene .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[37] Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine [J].

Lo Sasso, Bruna ;

Giglio, Rosaria Vincenza ;

Vidali, Matteo ;

Scazzone, Concetta ;

Bivona, Giulia ;

Gambino, Caterina Maria ;

Ciaccio, Anna Maria ;

Agnello, Luisa ;

Ciaccio, Marcello .

DIAGNOSTICS, 2021, 11 (07)

[38] Antibody Response After a Fifth Dose (Third Booster) of BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers [J].

Saiag, Esther ;

Gamzu, Ronni ;

Padova, Hagit ;

Paran, Yael ;

Goldiner, Ilana ;

Cohen, Neta ;

Bomze, David .

JOURNAL OF CLINICAL MEDICINE, 2024, 13 (21)

[39] Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine [J].

Takahashi, Wataru ;

Mizuno, Toshiko ;

Hara, Kaori ;

Ara, Yoshiaki ;

Hurutani, Rikiya ;

Agatsuma, Toshihiko ;

Fujimori, Minoru .

INTERNAL MEDICINE, 2022, 61 (21) :3205-3210

[40] Nonepisodic Angioedema with Eosinophilia Following Receipt of the BNT162b2 mRNA COVID-19 Vaccine [J].

Koda, Tamaki ;

Natsumoto, Bunki ;

Shoda, Hirofumi ;

Fujio, Keishi .

INTERNAL MEDICINE, 2023, 62 (20) :3063-3067

← 1 2 3 4 5 →